Document is current
Any future updates will be listed below
-
Authors
Bergeron, Paul https://orcid.org/0009-0004-1150-2003
Dos Santos, Morgane
Sitterle, Lisa
Tarlet, Georges https://orcid.org/0000-0002-4756-5127
Lavigne, Jeremy
Liu, Winchygn
Gerbé de Thoré, Marine
Clémenson, Céline
Meziani, Lydia https://orcid.org/0000-0002-1127-0183
Schott, Cathyanne
Mazzaschi, Giulia
Berthelot, Kevin https://orcid.org/0000-0001-7575-2678
Benadjaoud, Mohamed Amine
Milliat, Fabien
Deutsch, Eric https://orcid.org/0000-0002-8223-3697
Mondini, Michele https://orcid.org/0000-0001-5803-0083
- License Information
-
More Information
Article History
Received: 11 October 2023
Accepted: 29 September 2024
First Online: 14 October 2024
Competing interests
: P.B., L.S., W.L., M.G.D.T., C.C., L.M., C.S., G.M., E.D. and M.M. declare grants from Roche Genentech, AstraZeneca, Merck Serono, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and MSD, outside the submitted work. E.D. declares consulting fees from Graegis. The remaining authors declare no competing interests.
